Advertisement
Advertisement
IVA
Inventiva S.A. - ADR
3.80
USDSponsored
+0.17
+4.68%
Nov 06, 15:59 UTC -5
Closed
After-Market
3.75
-0.05
-1.45%
Inventiva S.A. - ADR (IVA) Earnings
IVA Earnings Reports
Positive Surprise Ratio
IVA beat 1 of 1 last estimates.
100%
Next Report
Date of Next Report
Nov 23, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/--
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q3 25 (Revenue/ EPS)
--
/--
Inventiva S.A. - ADR earnings per share and revenue
On Sep 28, 2026, IVA reported earnings of -0.25 USD per share (EPS) for Q2 26, beating the estimate of -0.37 USD, resulting in a 33.55% surprise. Revenue reached 20.00 thousand, compared to an expected 3.87 million, with a -99.48% difference. The market reacted with a +4.75% price change (close before vs. close after earnings).
Looking ahead to Q3 26, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Novavax Inc
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.34
Actual
-$0.19
Surprise
+44.56%
Eton Pharmaceutcials, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.31
Actual
$1.06
Surprise
+232.50%
Castle Biosciences, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.13
Surprise
+65.32%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.29
Actual
$0.03
Surprise
+110.09%
PUMA BIOTECHNOLOGY INC
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.09
Actual
$0.15
Surprise
+63.40%
Allogene Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.15
Actual
-$0.15
Surprise
+0.33%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.69
Actual
-$0.26
Surprise
+62.44%
Anika Therapeutics Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
$0.06
Actual
$0.28
Surprise
+373.86%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Vera Therapeutics, Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$1.65
Actual
-$1.30
Surprise
+21.33%
FAQ
What were Inventiva S.A. - ADR's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Inventiva S.A. - ADR reported EPS of -$0.25, beating estimates by 33.55%, and revenue of $20.00K, -99.48% below expectations.
How did the market react to Inventiva S.A. - ADR's Q2 2026 earnings?
The stock price moved up 4.75%, changed from $3.37 before the earnings release to $3.53 the day after.
When is Inventiva S.A. - ADR expected to report next?
The next earning report is scheduled for Nov 23, 2026.
What are the forecasts for Inventiva S.A. - ADR's next earnings report?
Based on --
analysts, Inventiva S.A. - ADR is expected to report EPS of -- and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.